ArticleBiomolecules2026
Electrospun PLA/PVP K90 Biphasic-Release Sublingual Film for Motion Sickness Treatment.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Electrospun Eudragit Nanofiber Mats as a Buccal Delivery Platform for Triamcinolone Acetonide.ACS omega · 2026Article
- Article
- Biomimetic Vascular Scaffold with Seamless Electrospun Aligned Nanofiber Conduit and 3D-Printed Coil Reinforcement.Advanced healthcare materials · 2026Article
- Article
- Core-Sheath Nanofibers From a Modified Coaxial Electrospinning for Transdermal Delivery of Finasteride.ChemistryOpen · 2026Article
- Fast Dissolving Resveratrol-Polyvinylpyrrolidone Nanofibrous Films Fabricated in Bulk Using a Special Hole Electrospinning Technique.Polymers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To overcome the limitations of traditional motion sickness medications-slow onset of action, short duration of efficacy, and poor patient compliance-this study employed coaxial electrospinning technology. Poly(lactic acid) (PLA) and polyvinylpyrrolidone K90 (PVP K90) were used as composite carrier materials. The sheath layer is composed of highly hydrophilic PVP K90, loaded with the antihistamine diphenhydramine (DPH). The core layer, composed of biodegradable PLA with excellent sustained-release properties, carries the anticholinergic drug scopolamine hydrobromide (SH). This core-sheath nanostructured nanofiber sublingual film delivers dual anti-motion sickness drugs. A series of characterization tests revealed that the sublingual membrane exhibits a linear morphology with a distinct core-shell nanostructure. The drugs DPH and SH are distributed in an amorphous state within the sheath and core layers, respectively. Wetting performance tests indicate that the membrane's wettability falls between those of monofilament membranes. In vitro drug release experiments revealed that DPH exhibited a "rapid onset + sustained release" biphasic profile, with cumulative release reaching 60% within 2 h and approaching complete release by 10 h, primarily via Fickian diffusion (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.